Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2025-03-25 00:00:00 ET · period of report 2025-03-21 · accession 0001415889-25-008942 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-03-25 | 2025-03-21 | LYEL | Ramachandra Sumant | Dir | P - Purchase | $0.58 | +200.0K | 200.0K | New | +$116.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-21 | P | A | 200,000 | $0.58 | 200,000 | I Grantor and Trustee | — | — | (F1) The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.5487 to $0.5879, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range. (F2) Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12. |